SCOPE 2019

Tech is advancing, but uncertainty creates an ‘opposing effect’ to positive movement

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/z_wei)
(Image: Getty/z_wei)

Related tags: CRF Bracket, Technology, eConsent, eCOA

The industry has advanced to a point that should justify the financial investment in new technology, though uncertainty, and a lack of support, are hindering movement.

Jeff Lee, product lead for patient engagement and eConsent at CRF Bracket, is speaking this week at the 10th Annual Summit of Clinical Operations Executives (SCOPE) in Orlando, FL.

In his session, Lee will talk about three solution areas: eConsent, eCOA, and patient engagement. While the barriers for adoption of these differ somewhat, the top three are adequate budget within the overall study budget, clear value proposition, and regulatory considerations. 

“As an industry, we are enhancing our technologies so they can be delivered more efficiently,” ​said Lee. “We’re also seeing a gradual accumulation of case studies and journal articles demonstrating the positive impact of these technologies,”

Backed by these trends, Lee said the industry should have the validation to budget for technology appropriately. Still, the industry faces uncertainty as it pertains to the regulator's view of topics such as electronic signatures and Software as Medical Device (SaMD​) regulations. Lee noted it could also be quite simply, a lack of support.

“This creates an opposing effect to the positive movement in the other areas,”​ he said.

Challenges, changes, and continued adoption

Implementing eConsent does pose its own set of challenges, including the provisioning of single-use devices to sites, gaining regulatory acceptance of different forms of electronic signature, and handling complex studies with disparate consent documents.

However, these are modest challenges compared to the overall scheme of eClinical technologies, said Lee. And yet, the adoption of eConsent remains in the low single-digits. 

“This low adoption means that studies still struggle with protocol deviations due to poor protocol comprehensions, as well as critical regulator findings due to erroneous consenting activities, among other problems,”​ explained Lee.

Offered as a stand-alone solution, Lee said eConsent has limited opportunity to be adopted by studies moving forward.

“However, in the coming years, we will see eConsent delivered together with other solutions (like Patient Engagement, IRT, eCOA) such that it has a lower unique cost to the sponsor and therefore has a stronger ROI,”​ he said. “This will promote continued adoption to the point, within 5 years, eConsent will have surpassed where eCOA is today in terms of adoption.”

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars